keyword
MENU ▼
Read by QxMD icon Read
search

Glioma AND IL-13

keyword
https://www.readbyqxmd.com/read/27734611/hyperbaric-oxygen-therapy-sensitizes-nimustine-treatment-for-glioma-in-mice
#1
Zhaohui Lu, Jiawei Ma, Bing Liu, Chungang Dai, Tao Xie, Xiaoyu Ma, Ming Li, Jun Dong, Qing Lan, Qiang Huang
Nimustine (ACNU) has antitumor activities in patients with malignant glioma. Hyperbaric oxygen (HBO) may enhance the efficacy of certain therapies that are hampered by the hypoxic microenvironment. We examined the combined effects of ACNU and HBO in a GFP transgenic nude mice bearing human glioma model. Mice inoculated with human glioma cells SU3 were randomly divided into the four groups: (A) the control group, (B) the HBOT (HBO therapy) group, (C) the ACNU group, and (D) the HBOT+ACNU group. Tumor size was measured at the indicated time intervals with a caliper; mice were sacrificed 28 days after treatment, and immunohistochemistry staining and western blot analysis were carried out...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27636161/enhanced-antiglioblastoma-efficacy-of-neovasculature-and-glioma-cells-dual-targeted-nanoparticles
#2
Lingyan Lv, Yan Jiang, Xin Liu, Baoyan Wang, Wei Lv, Yue Zhao, Huihui Shi, Quanyin Hu, Hongliang Xin, Qunwei Xu, Zhen Gu
Combining treatment of anticancer cells and antiangiogenesis is considered to be a potential targeted strategy for brain glioblastoma therapy. In this study, by utilizing the overexpression of Interleukin 13 receptor α2 (IL-13Rα2) on the glioma cells and heparan sulfate on neovascular endothelial cells, we developed a paclitaxel (PTX) loaded Pep-1 and CGKRK peptide-modified PEG-PLGA nanoparticle (PC-NP-PTX) for glioma cells and neovasculature dual-targeted chemotherapy to enhance the antiglioma efficacy. There were significant differences both on the enhancement of cellular uptake in HUVEC and C6 cells and on the improvement of in vitro antiglioma activity in the respect of proliferation, tumor spheroid growth, tube formation, and migration between PC-NP-PTX and Taxol and NP-PTX...
October 3, 2016: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/27623944/il-13-receptor-%C3%AE-2-stimulates-human-glioma-cell-growth-and-metastasis-through-the-src-pi3k-akt-mtor-signaling-pathway
#3
Ming Tu, Wei Wange, Lin Cai, Penglei Zhu, Zhichao Gao, Weiming Zheng
Glioma is a malignant tumor that affects all kinds of people all over the world. It demonstrates remarkable infiltrative and invasive features. The high expression of interleukin-13 receptor subunit alpha-2 (IL-13Rα2) reportedly plays a pivotal role in some cancers. However, whether IL-13Rα2 contributes to glioma remains unknown. This study demonstrates that IL-13Rα2 is significantly up-regulated in human glioma tissue samples. It is also associated with late stages of disease progression and diminished survival in glioma patients...
September 14, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/27518456/pegylated-polyamidoamine-dendrimer-conjugated-with-tumor-homing-peptide-as-a-potential-targeted-delivery-system-for-glioma
#4
Yan Jiang, Lingyan Lv, Huihui Shi, Yabing Hua, Wei Lv, Xiuzhen Wang, Hongliang Xin, Qunwei Xu
Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system (CNS) tumor with a short survival time. The failure of chemotherapy is ascribed to the low transport of chemotherapeutics across the Blood Brain Tumor Barrier (BBTB) and poor penetration into tumor tissue. In order to overcome the two barriers, small nanoparticles with active targeted capability are urgently needed for GBM drug delivery. In this study, we proposed PEGylated Polyamidoamine (PAMAM) dendrimer nanoparticles conjugated with glioma homing peptides (Pep-1) as potential glioma targeting delivery system (Pep-PEG-PAMAM), where PEGylated PAMAM dendrimer nanoparticle was utilized as carrier due to its small size and perfect penetration into tumor and Pep-1 was used to overcome BBTB via interleukin 13 receptor α2 (IL-13Rα2) mediated endocytosis...
November 1, 2016: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/27424080/tristetraprolin-exerts-tumor-suppressive-functions-on-the-tumorigenesis-of-glioma-by-targeting-il-13
#5
Bo Zeng, Danhua Zhu, Zhipeng Su, Zequn Li, Zhengquan Yu
The RNA-binding protein tristetraprolin (TTP) is an adenine/uridine (AU)-rich elements (AREs)-binding protein that can induce the decay of AREs containing mRNAs. In this study, we demonstrated that TTP is significantly down-regulated in human glioma tissue samples and cell lines. It is also associated with diminished survival in glioma patients. Gain- and loss-of-function studies demonstrated that TTP inhibited the growth, migration and invasion of glioma cells through regulation of interleukin (IL)-13. Furthermore, mechanistic investigations showed that TTP attenuated activation of PI3K/Akt/mTOR pathway by IL-13, and the ectopic expression of IL-13 markedly abrogated the anti-invasive effect of TTP...
October 2016: International Immunopharmacology
https://www.readbyqxmd.com/read/26700665/note-of-the-methodological-flaws-in-the-paper-entitled-polymorphisms-in-il-4-il-13-pathway-genes-and-glioma-risk-an-updated-meta-analysis
#6
Ting-Ting Wang, Jin-Mei Li, Dong Zhou
With great interest, we read the paper "Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis" (by Chen PQ et al.) [1], which has reached important conclusions about the relationship between polymorphisms in interleukin (IL)-4/IL-13 pathway genes and glioma risk. Through quantitative analysis, the meta-analysis found no association between IL-4/IL-13 pathway genetic polymorphisms and glioma risk (Chen et al. in Tumor Biol 36:121-127, 2015). The meta-analysis is the most comprehensive study of polymorphisms in the IL-4/IL-13 pathway and glioma risk...
January 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/26519740/mri-contrast-agent-for-targeting-glioma-interleukin-13-labeled-liposome-encapsulating-gadolinium-dtpa
#7
Xiaoli Liu, Achuthamangalam B Madhankumar, Patti A Miller, Kari A Duck, Susan Hafenstein, Elias Rizk, Becky Slagle-Webb, Jonas M Sheehan, James R Connor, Qing X Yang
BACKGROUND: Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in glioma, can be used as a target moiety. We hypothesized that liposomes conjugated with IL-13 and encapsulating MRI contrast agent are capable of passing through an intact BBB and producing MRI contrast with greater sensitivity...
May 2016: Neuro-oncology
https://www.readbyqxmd.com/read/26516307/single-nucleotide-polymorphisms-in-il-10-il-12p40-and-il-13-genes-and-susceptibility-to-glioma
#8
Haidar A Shamran, Haidar F Ghazi, Ahmed Al-Salman, Ahmad A Al-Juboory, Dennis D Taub, Robert L Price, Mitzi Nagarkatti, Prakash S Nagarkatti, Udai P Singh
Glioma is one of the most aggressive and most common tumors of the central nervous system (CNS) in humans. The exact causes of glioma are not well known, but evidence suggests the involvement of genetic factors in addition to environmental risk factors. The present study aimed to determine whether polymorphisms in IL-10-1082A/G, IL-12p40 1188C/A, and IL-13+2044G/A (rs20541) are associated with the incidence of glioma in Iraqi patients. Ninety-six patients with different grades of glioma and 40 apparently healthy individuals were recruited...
2015: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/25472582/polymorphisms-in-il-4-il-13-pathway-genes-and-glioma-risk-an-updated-meta-analysis
#9
Peiqin Chen, Chao Chen, Kun Chen, Tao Xu, Chun Luo
Polymorphisms in interleukin (IL)-4/IL-13 pathway genes have previously been reported to be associated with glioma susceptibility, although results are inconsistent. We therefore performed an updated meta-analysis to determine a more precise estimation of this relationship. Twelve eligible studies were identified by searching PubMed, EMBASE, Web of Science, and the Cochrane Library electronic databases. Nine polymorphisms in genes within the IL-4/IL-13 pathway (IL-4 rs2243250, rs2070874, rs2243248, IL-4R rs1805011, rs1805012, rs1805015, rs1801275, and IL-13 rs20541 and rs1800925) were assessed for their relationship with glioma risk by computing odds ratios (ORs) and corresponding 95 % confidence intervals (CIs)...
January 2015: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/25464980/stable-luciferase-expression-does-not-alter-immunologic-or-in-vivo-growth-properties-of-gl261-murine-glioma-cells
#10
Aaron J Clark, Michael Safaee, Taemin Oh, Michael E Ivan, Vamsi Parimi, Rintaro Hashizume, Tomoko Ozawa, Charles D James, Orin Bloch, Andrew T Parsa
BACKGROUND: GL261 cells are murine glioma cells that demonstrate proliferation, invasion, and angiogenesis when implanted in syngeneic C57BL/6 mice, providing a highly useful immunocompetent animal model of glioblastoma. Modification of tumor cells for luciferase expression enables non-invasive monitoring of orthotopic tumor growth, and has proven useful for studying glioblastoma response to novel therapeutics. However, tumor modification for luciferase has the potential for evoking host immune response against otherwise syngeneic tumor cells, thereby mitigating the tumor cells' value for tumor immunology and immunotherapy studies...
2014: Journal of Translational Medicine
https://www.readbyqxmd.com/read/24947060/analysis-of-biodistribution-of-intracranially-infused-radiolabeled-interleukin-13-receptor-targeted-immunotoxin-il-13pe-by-spect-ct-in-an-orthotopic-mouse-model-of-human-glioma
#11
Akiko Suzuki, Pamela Leland, Hisataka Kobayashi, Peter L Choyke, Elaine M Jagoda, Tomio Inoue, Bharat H Joshi, Raj K Puri
UNLABELLED: Interleukin-13 Pseudomonas exotoxin (IL-13PE), a targeted agent for interleukin-13 receptor α2 (IL-13Rα2)-expressing tumors, has been administered intracranially by convection-enhanced delivery (CED) for glioma therapy in several clinical trials including a randomized phase 3 clinical trial. However, its intracranial distribution was not optimally evaluated. We investigated the intracranial distribution of radiolabeled IL-13PE after CED in a murine model of glioblastoma multiforme...
August 2014: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/24787244/cytokine-induction-of-vcam-1-but-not-il13r%C3%AE-2-on-glioma-cells-a-tale-of-two-antibodies
#12
Vaidehi Mahadev, Renate Starr, Sarah L Wright, Catalina Martinez, Michael C Jensen, Michael E Barish, Stephen J Forman, Christine E Brown
The interleukin-13 receptor alpha2 (IL13Rα2) is a cell surface receptor that is over-expressed by a subset of high-grade gliomas, but not expressed at significant levels by normal brain tissue. For both malignant and non-malignant cells, IL13Rα2 surface expression is reported to be induced by various cytokines such as IL-4 or IL-13 and tumor necrosis factor (TNF). Our group has developed a therapeutic platform to target IL13Rα2-positive brain tumors by engineering human cytotoxic T lymphocytes (CTLs) to express the IL13-zetakine chimeric antigen receptor...
2014: PloS One
https://www.readbyqxmd.com/read/24723564/significance-of-interleukin-13-receptor-alpha-2-targeted-glioblastoma-therapy
#13
REVIEW
Bart Thaci, Christine E Brown, Emanuela Binello, Katherine Werbaneth, Prakash Sampath, Sadhak Sengupta
Glioblastoma multiforme (GBM) remains one of the most lethal primary brain tumors despite surgical and therapeutic advancements. Targeted therapies of neoplastic diseases, including GBM, have received a great deal of interest in recent years. A highly studied target of GBM is interleukin-13 receptor α chain variant 2 (IL13Rα2). Targeted therapies against IL13Rα2 in GBM include fusion chimera proteins of IL-13 and bacterial toxins, nanoparticles, and oncolytic viruses. In addition, immunotherapies have been developed using monoclonal antibodies and cell-based strategies such as IL13Rα2-pulsed dendritic cells and IL13Rα2-targeted chimeric antigen receptor-modified T cells...
October 2014: Neuro-oncology
https://www.readbyqxmd.com/read/24607217/in-vitro-and-in-vivo-intracellular-distribution-and-anti-glioblastoma-effects-of-docetaxel-loaded-nanoparticles-functioned-with-il-13-peptide
#14
Huile Gao, Shuang Zhang, Zhi Yang, Shijie Cao, Xinguo Jiang, Zhiqing Pang
An active targeting delivery system helps increase intracellular drug delivery, which is promising for the treatment of glioblastoma. Interleukin 13 (IL-13) peptide which was derived from IL-13 protein could specially bind with IL-13Rα2, a receptor highly expressed on glioblastoma cells but not on normal brain cells, suggesting IL-13 peptide is an optional ligand for glioblastoma targeted therapy. In this contribution, IL-13 peptide was functionalized to nanoparticles (ILNP) to form a glioblastoma targeted drug delivery system where docetaxel was used as a model drug...
May 15, 2014: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/24204956/glioma-il13r%C3%AE-2-is-associated-with-mesenchymal-signature-gene-expression-and-poor-patient-prognosis
#15
Christine E Brown, Charles D Warden, Renate Starr, Xutao Deng, Behnam Badie, Yate-Ching Yuan, Stephen J Forman, Michael E Barish
A major challenge for successful immunotherapy against glioma is the identification and characterization of validated targets. We have taken a bioinformatics approach towards understanding the biological context of IL-13 receptor α2 (IL13Rα2) expression in brain tumors, and its functional significance for patient survival. Querying multiple gene expression databases, we show that IL13Rα2 expression increases with glioma malignancy grade, and expression for high-grade tumors is bimodal, with approximately 58% of WHO grade IV gliomas over-expressing this receptor...
2013: PloS One
https://www.readbyqxmd.com/read/24030977/gm-csf-promotes-the-immunosuppressive-activity-of-glioma-infiltrating-myeloid-cells-through-interleukin-4-receptor-%C3%AE
#16
Gary Kohanbash, Kayla McKaveney, Masashi Sakaki, Ryo Ueda, Arlan H Mintz, Nduka Amankulor, Mitsugu Fujita, John R Ohlfest, Hideho Okada
Malignant gliomas are lethal cancers in the brain and heavily infiltrated by myeloid cells. Interleukin-4 receptor-α (IL-4Rα) mediates the immunosuppressive functions of myeloid cells, and polymorphisms in the IL-4Rα gene are associated with altered glioma risk and prognosis. In this study, we sought to evaluate a hypothesized causal role for IL-4Rα and myeloid suppressor cells in glioma development. In both mouse de novo gliomas and human glioblastoma cases, IL-4Rα was upregulated on glioma-infiltrating myeloid cells but not in the periphery or in normal brain...
November 1, 2013: Cancer Research
https://www.readbyqxmd.com/read/23982586/ligand-modified-nanoparticles-increases-cell-uptake-alters-endocytosis-and-elevates-glioma-distribution-and-internalization
#17
Huile Gao, Zhi Yang, Shuang Zhang, Shijie Cao, Shun Shen, Zhiqing Pang, Xinguo Jiang
Nanoparticles (NPs) were widely used in drugs/probes delivery for improved disease diagnosis and/or treatment. Targeted delivery to cancer cells is a highly attractive application of NPs. However, few studies have been performed on the targeting mechanisms of these ligand-modified delivery systems. Additional studies are needed to understand the transport of nanoparticles in the cancer site, the interactions between nanoparticles and cancer cells, the intracellular trafficking of nanoparticles within the cancer cells and the subcellular destiny and potential toxicity...
2013: Scientific Reports
https://www.readbyqxmd.com/read/23395224/association-between-polymorphisms-in-interleukin-4r%C3%AE-and-interleukin-13-and-glioma-risk-a-meta-analysis
#18
Guan Sun, Xiefeng Wang, Lei Shi, Xiao Yue, Linshan Fu, Chen Chen, Zhengyi Li, Tianhong Pan, Zhengqiang Wan
INTRODUCTION: It has been suggested that allergies are inversely associated with glioma risk. Single nucleotide polymorphisms in two allergy-related genes [interleukin (IL)-4Rα, IL-13] have been implicated in susceptibility to glioma; however, results from the published studies remained inconclusive. METHODS: To derive a more precise relationship, we conducted a meta-analysis including seven case-control studies that investigated the influence of IL-4Rα rs1801275 and IL13 rs20541 polymorphisms on glioma risk...
June 2013: Cancer Epidemiology
https://www.readbyqxmd.com/read/23186108/profound-tumor-specific-th2-bias-in-patients-with-malignant-glioma
#19
Shinji Shimato, Lisa M Maier, Richard Maier, Jeffrey N Bruce, Richard C E Anderson, David E Anderson
BACKGROUND: Vaccination against tumor-associated antigens is one promising approach to immunotherapy against malignant gliomas. While previous vaccine efforts have focused exclusively on HLA class I-restricted peptides, class II-restricted peptides are necessary to induce CD4+ helper T cells and sustain effective anti-tumor immunity. In this report we investigated the ability of five candidate peptide epitopes derived from glioma-associated antigens MAGE and IL-13 receptor α2 to detect and characterize CD4+ helper T cell responses in the peripheral blood of patients with malignant gliomas...
2012: BMC Cancer
https://www.readbyqxmd.com/read/23103669/the-protein-pheromone-er-1-of-the-ciliate-euplotes-raikovi-stimulates-human-t-cell-activity-involvement-of-interleukin-2-system
#20
Davide Cervia, Elisabetta Catalani, Maria Cristina Belardinelli, Cristiana Perrotta, Simona Picchietti, Claudio Alimenti, Giovanni Casini, Anna Maria Fausto, Adriana Vallesi
Water-soluble protein signals (pheromones) of the ciliate Euplotes have been supposed to be functional precursors of growth factors and cytokines that regulate cell-cell interaction in multi-cellular eukaryotes. This work provides evidence that native preparations of the Euplotes raikovi pheromone Er-1 (a helical protein of 40 amino acids) specifically increases viability, DNA synthesis, proliferation, and the production of interferon-γ, tumor necrosis factor-α, interleukin (IL)-1β, IL-2, and IL-13 in human Jurkat T-cells...
February 1, 2013: Experimental Cell Research
keyword
keyword
83196
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"